JP2004504348A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004504348A5 JP2004504348A5 JP2002513460A JP2002513460A JP2004504348A5 JP 2004504348 A5 JP2004504348 A5 JP 2004504348A5 JP 2002513460 A JP2002513460 A JP 2002513460A JP 2002513460 A JP2002513460 A JP 2002513460A JP 2004504348 A5 JP2004504348 A5 JP 2004504348A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- ring
- formula
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 22
- 125000000217 alkyl group Chemical group 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- -1 amino, aminocarbonyl Chemical group 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 125000000623 heterocyclic group Chemical group 0.000 description 7
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 description 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 208000033679 diabetic kidney disease Diseases 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 229910052717 sulfur Chemical group 0.000 description 3
- 125000004571 thiomorpholin-4-yl group Chemical group N1(CCSCC1)* 0.000 description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 2
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 125000005530 alkylenedioxy group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- LYLFQLCLUXOFOL-UHFFFAOYSA-N 2-(4,5-dimethyl-1,3-thiazol-3-ium-3-yl)-1-phenylethanone Chemical class CC1=C(C)SC=[N+]1CC(=O)C1=CC=CC=C1 LYLFQLCLUXOFOL-UHFFFAOYSA-N 0.000 description 1
- NWYBJPXXICNVLX-UHFFFAOYSA-M 2-(4,5-dimethyl-1,3-thiazol-3-ium-3-yl)-1-phenylethanone;bromide Chemical group [Br-].CC1=C(C)SC=[N+]1CC(=O)C1=CC=CC=C1 NWYBJPXXICNVLX-UHFFFAOYSA-M 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010052337 Diastolic dysfunction Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 1
- MKOMESMZHZNBIZ-UHFFFAOYSA-M alagebrium Chemical group [Cl-].CC1=C(C)SC=[N+]1CC(=O)C1=CC=CC=C1 MKOMESMZHZNBIZ-UHFFFAOYSA-M 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21827300P | 2000-07-13 | 2000-07-13 | |
| US25943100P | 2000-12-29 | 2000-12-29 | |
| US25924201P | 2001-01-02 | 2001-01-02 | |
| US29643501P | 2001-06-06 | 2001-06-06 | |
| PCT/US2001/022214 WO2002007725A1 (en) | 2000-07-13 | 2001-07-13 | Method for treating fibrotic diseases or other indications ic |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004504348A JP2004504348A (ja) | 2004-02-12 |
| JP2004504348A5 true JP2004504348A5 (enExample) | 2009-04-09 |
Family
ID=27499106
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002514116A Withdrawn JP2004504389A (ja) | 2000-07-13 | 2001-07-13 | シアノメチル置換化チアゾリウム及びイミダゾリウム、並びにタンパク質老化と関連する疾患の治療 |
| JP2002513460A Pending JP2004504348A (ja) | 2000-07-13 | 2001-07-13 | 線維症性疾患または他の適応症ｉｃを治療する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002514116A Withdrawn JP2004504389A (ja) | 2000-07-13 | 2001-07-13 | シアノメチル置換化チアゾリウム及びイミダゾリウム、並びにタンパク質老化と関連する疾患の治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (8) | US6610716B2 (enExample) |
| EP (3) | EP2085086A3 (enExample) |
| JP (2) | JP2004504389A (enExample) |
| AT (1) | ATE304849T1 (enExample) |
| AU (4) | AU2001280551B9 (enExample) |
| CA (2) | CA2415362A1 (enExample) |
| DE (1) | DE60113548T2 (enExample) |
| ES (1) | ES2251500T3 (enExample) |
| MX (2) | MXPA03000386A (enExample) |
| WO (2) | WO2002007725A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| EP1257272A4 (en) * | 2000-02-23 | 2004-12-15 | Alteon Inc | THIAZOLIUM COMPOUNDS AND TREATMENTS OF DISEASES RELATED TO PROTEIN AGING |
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| CA2415362A1 (en) * | 2000-07-13 | 2002-01-31 | Alteon, Inc. | Method for treating fibrotic diseases or other indications |
| US7199102B2 (en) * | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| WO2002053161A1 (en) | 2000-12-29 | 2002-07-11 | Alteon, Inc. | Method for treating fibrotic diseases or other indications |
| US7226928B2 (en) | 2001-06-15 | 2007-06-05 | 3M Innovative Properties Company | Methods for the treatment of periodontal disease |
| CA2449754A1 (en) * | 2001-06-15 | 2002-12-27 | 3M Innovative Properties Company | Immune response modifiers for the treatment of periodontal disease |
| WO2003099241A2 (en) | 2002-05-23 | 2003-12-04 | Tony Maniscalco | Sunscreen compositions and methods of use thereof |
| US7144570B2 (en) * | 2002-05-23 | 2006-12-05 | Alteon, Inc. | Sunscreen compositions and methods of use thereof |
| US20050014747A1 (en) * | 2003-04-18 | 2005-01-20 | Emily Reinhard | Dihydrothiazine prodrugs of thiazolium agents |
| US8871782B2 (en) | 2003-10-03 | 2014-10-28 | 3M Innovative Properties Company | Alkoxy substituted imidazoquinolines |
| RU2409576C2 (ru) | 2003-11-25 | 2011-01-20 | 3М Инновейтив Пропертиз Компани | Системы, содержащие имидазольное кольцо с заместителями, и способы их получения |
| US20050191245A1 (en) * | 2004-02-27 | 2005-09-01 | Adams Christopher P. | Nasal administration of calcium channel, blockers for treatment of hypertension and other cardiovascular disorders |
| US7840263B2 (en) | 2004-02-27 | 2010-11-23 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression |
| US7838552B2 (en) | 2004-06-04 | 2010-11-23 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
| ATE493973T1 (de) | 2004-06-04 | 2011-01-15 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
| US7803838B2 (en) | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
| US7764995B2 (en) * | 2004-06-07 | 2010-07-27 | Cardiac Pacemakers, Inc. | Method and apparatus to modulate cellular regeneration post myocardial infarct |
| US7729761B2 (en) * | 2004-07-14 | 2010-06-01 | Cardiac Pacemakers, Inc. | Method and apparatus for controlled gene or protein delivery |
| US7828711B2 (en) * | 2004-08-16 | 2010-11-09 | Cardiac Pacemakers, Inc. | Method and apparatus for modulating cellular growth and regeneration using ventricular assist device |
| EP1799242A4 (en) * | 2004-09-16 | 2009-11-11 | Univ California | TYPE G PEPTIDES AND OTHER ACTIVE SUBSTANCES TO REDUCE ATHEROSCLEROSIS AND OTHER DISEASES |
| CA2595067A1 (en) | 2004-12-06 | 2006-06-15 | The Regents Of The University Of California | Methods for improving the structure and function of arterioles |
| US7981065B2 (en) | 2004-12-20 | 2011-07-19 | Cardiac Pacemakers, Inc. | Lead electrode incorporating extracellular matrix |
| US8060219B2 (en) | 2004-12-20 | 2011-11-15 | Cardiac Pacemakers, Inc. | Epicardial patch including isolated extracellular matrix with pacing electrodes |
| US9248127B2 (en) | 2005-02-04 | 2016-02-02 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
| US20080293639A1 (en) * | 2005-04-29 | 2008-11-27 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| US7774057B2 (en) | 2005-09-06 | 2010-08-10 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression for cardiac protection |
| ITMI20052216A1 (it) * | 2005-11-18 | 2007-05-19 | Dipharma Spa | Procedimento per la preparazione di ziprasidone |
| CN101007789B (zh) * | 2006-01-27 | 2014-08-20 | 北京摩力克科技有限公司 | 取代五元氮杂环盐类化合物及其治疗蛋白老化相关疾病的用途 |
| WO2009023207A1 (en) * | 2007-08-13 | 2009-02-19 | Synvista Therapeutics, Inc. | Thiazolium compounds for treating gastrointestinal complications |
| WO2009051804A1 (en) * | 2007-10-18 | 2009-04-23 | Synvista Therapeutics, Inc. | Thiazolium compounds for treating or preventing diseases associated with insulin resistance |
| CN101983057A (zh) * | 2008-01-30 | 2011-03-02 | 新加坡科技研究局 | 用咪唑和咪唑啉化合物治疗纤维变性和癌症的方法 |
| TNSN08110A1 (en) * | 2008-03-11 | 2009-07-14 | Rekik Raouf Dr | Drug delivery to the anterior and posterior segment of the eye from drops |
| US20110028513A1 (en) * | 2008-03-31 | 2011-02-03 | Lang Zhuo | Method for treating neurological disorders with imidazolium and imidazolinium compounds |
| CN104277011A (zh) * | 2013-07-09 | 2015-01-14 | 中国人民解放军军事医学科学院毒物药物研究所 | 噻唑内盐类化合物及其治疗蛋白老化相关疾病的用途 |
| WO2015051258A1 (en) | 2013-10-03 | 2015-04-09 | David Spiegel | Crosslink breakers for preservation of biological substances |
| WO2017191234A1 (en) * | 2016-05-06 | 2017-11-09 | Unicyte Ev Ag | Pharmaceutical carriers containing mirnas for use in the treatment of fibrotic diseases caused by hyperglycemia |
| CN106505185B (zh) * | 2016-11-16 | 2019-11-15 | 南京师范大学 | 一种锑/氮掺杂碳复合物及其制备方法和应用 |
| KR20210080261A (ko) * | 2019-12-20 | 2021-06-30 | 가천대학교 산학협력단 | 신규한 티아졸 유도체 및 이의 용도 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9210096D0 (en) * | 1992-05-11 | 1992-06-24 | Fujisawa Pharmaceutical Co | 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid derivatives and their preparation |
| US5656261A (en) | 1995-01-18 | 1997-08-12 | The Picower Institute For Medical Research | Preventing and reversing advanced glycosylation endproducts |
| DK0808163T3 (da) * | 1995-01-18 | 2003-11-10 | Alteon Inc | Anvendelse af thiazoliumforbindelser til at forhindre og ændre dannelse af fremskredne glycosyleringsslutprodukter |
| FI119756B (fi) * | 1995-01-18 | 2009-03-13 | Alteon Inc | Tiatsoliumyhdisteiden käyttö pitkälle edenneen glykosylaation lopputuotteiden muodostumisen estossa ja suunnan muutoksessa |
| US5850840A (en) * | 1995-11-15 | 1998-12-22 | Alteon Inc. | Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts |
| JPH107709A (ja) * | 1996-06-24 | 1998-01-13 | Toyo Ink Mfg Co Ltd | 感エネルギー線活性剤組成物、それを用いた感応性組成物ならびに画像形成用組成物 |
| US6391899B1 (en) * | 1998-07-17 | 2002-05-21 | North Shore—Long Island Jewish Research Institute | Compounds and compositions for treating tissue ischemia |
| AU6384099A (en) * | 1998-08-31 | 2000-03-21 | Proteotech, Inc. | Blended compositions for treatment of alzheimer's disease and other amyloidoses |
| US6121300A (en) * | 1998-11-10 | 2000-09-19 | Wagle; Dilip R. | Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts |
| AU2001287289A1 (en) * | 2000-04-03 | 2001-10-15 | Bristol-Myers Squibb Company | Vasopeptidase inhibitors to treat isolated systolic hypertensions |
| CA2415362A1 (en) * | 2000-07-13 | 2002-01-31 | Alteon, Inc. | Method for treating fibrotic diseases or other indications |
| US20030176426A1 (en) * | 2000-07-13 | 2003-09-18 | Alteon, Inc. | Method for treating fibrotic diseases or other indications with imidazolium agents |
| DE60130030T2 (de) * | 2000-12-29 | 2008-04-30 | Alteon Inc. | Verfahren zur behandlung von glaukom |
| US6853703B2 (en) * | 2001-07-20 | 2005-02-08 | Siemens Medical Solutions Usa, Inc. | Automated delivery of treatment fields |
-
2001
- 2001-07-13 CA CA002415362A patent/CA2415362A1/en not_active Abandoned
- 2001-07-13 AT AT01958941T patent/ATE304849T1/de not_active IP Right Cessation
- 2001-07-13 DE DE60113548T patent/DE60113548T2/de not_active Expired - Fee Related
- 2001-07-13 MX MXPA03000386A patent/MXPA03000386A/es active IP Right Grant
- 2001-07-13 JP JP2002514116A patent/JP2004504389A/ja not_active Withdrawn
- 2001-07-13 AU AU2001280551A patent/AU2001280551B9/en not_active Ceased
- 2001-07-13 CA CA002415054A patent/CA2415054A1/en not_active Abandoned
- 2001-07-13 WO PCT/US2001/022214 patent/WO2002007725A1/en not_active Ceased
- 2001-07-13 EP EP09156991A patent/EP2085086A3/en not_active Ceased
- 2001-07-13 AU AU8055101A patent/AU8055101A/xx active Pending
- 2001-07-13 US US09/905,035 patent/US6610716B2/en not_active Expired - Fee Related
- 2001-07-13 AU AU2001280546A patent/AU2001280546B2/en not_active Ceased
- 2001-07-13 ES ES01958941T patent/ES2251500T3/es not_active Expired - Lifetime
- 2001-07-13 JP JP2002513460A patent/JP2004504348A/ja active Pending
- 2001-07-13 EP EP01958941A patent/EP1303501B1/en not_active Expired - Lifetime
- 2001-07-13 AU AU8054601A patent/AU8054601A/xx active Pending
- 2001-07-13 US US09/905,188 patent/US20020068729A1/en not_active Abandoned
- 2001-07-13 WO PCT/US2001/022200 patent/WO2002008210A1/en not_active Ceased
- 2001-07-13 EP EP01958946A patent/EP1305024A4/en not_active Withdrawn
- 2001-07-13 MX MXPA03000388A patent/MXPA03000388A/es not_active Application Discontinuation
- 2001-12-31 US US10/037,447 patent/US7166625B2/en not_active Expired - Fee Related
-
2003
- 2003-08-21 US US10/645,011 patent/US20050032865A1/en not_active Abandoned
-
2004
- 2004-06-21 US US10/873,056 patent/US20040235837A1/en not_active Abandoned
-
2006
- 2006-05-10 US US11/432,034 patent/US20070099892A1/en not_active Abandoned
-
2009
- 2009-01-09 US US12/319,569 patent/US20090124673A1/en not_active Abandoned
- 2009-01-09 US US12/319,570 patent/US20090124674A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004504348A5 (enExample) | ||
| US6090807A (en) | Use of heterocyclic compounds | |
| CA2448306A1 (en) | Method for treating fibrotic diseases or other indications | |
| JP2005539088A5 (enExample) | ||
| JP2005537312A5 (enExample) | ||
| WO1992009279A1 (fr) | Derive de 2-arylthiazole et composition pharmaceutique contenant ce derive | |
| JP2004506736A5 (enExample) | ||
| JP2003513961A (ja) | シクロオキシゲナーゼ−２の阻害剤である５−アリール−１ｈ−１，２，４−トリアゾール化合物とそれを含む医薬品組成物 | |
| NO20055655D0 (no) | Anvendelse av azetidinkarboksamidderivater i terapi | |
| HU223530B1 (hu) | 4-Alkil-imidazol-származékok | |
| CA2416874A1 (en) | 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists | |
| US6596745B2 (en) | Method for treating fibrotic diseases with azolium chroman compounds | |
| NO20052730L (no) | Aminoalkosyindoler som 5-HT6-reseptorligander for behandling av CNS-lidelser | |
| JP2004521150A5 (enExample) | ||
| JP2004520329A5 (enExample) | ||
| IL180171A0 (en) | Novel 2-substituted d-homo-estra-1,3,5(10)-trienes as inhibitors of 17??- hydroxysteroid dehydrogenase type 1 | |
| JP2006501245A5 (enExample) | ||
| JP2005513103A5 (enExample) | ||
| RU2001116601A (ru) | Новые производные пиримидина и способы их получения | |
| CA2441331A1 (en) | Bicyclic guanidine derivatives and therapeutic uses thereof | |
| FI955387A0 (fi) | 4(p-fluorifenyyli)-3-((3,4-(metyleenioksi)fenoksi)metyyli)-piperidiinin N-p-halobentsoyylimetyylijohdannaiset | |
| JP2008520611A5 (enExample) | ||
| KR20050113627A (ko) | 수용성 페닐피리다진 유도체 및 이를 함유하는 의약 | |
| KR20040039377A (ko) | 수용성 페닐피리다진 유도체 및 이를 함유하는 의약 | |
| CA2511337A1 (en) | Oxazoles as mglur1 enhancer |